{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"1"}],"units":"Participants"}],"description":"Tumor assessment was performed using RECIST v1.1 for Participants with All Other Tumours.","groups":[{"description":"Participants with Dnet In Noonan's Syndrome Tumor With RAS/RAF/MEK/ERK Pathway Activation.","id":"OG000","title":"Dnet In Noonan's Syndrome Tumor With RAS/RAF/MEK/ERK Pathway Activation"},{"description":"Participants with Malignant Peripheral Nerve Sheath Tumor.","id":"OG001","title":"Malignant Peripheral Nerve Sheath Tumor"},{"description":"Participants with Metastatic Mediastinal Yolksac Tumor With RAS/RAF/MEK/ERK Pathway Activation.","id":"OG002","title":"Metastatic Mediastinal Yolksac Tumor With RAS/RAF/MEK/ERK Pathway Activation"},{"description":"Participants with Non-Rhabdomyosarcoma Soft Tissue Sarcoma.","id":"OG003","title":"Non-Rhabdomyosarcoma Soft Tissue Sarcoma"},{"description":"Participants with Plexiform Neurofibroma.","id":"OG004","title":"Plexiform Neurofibroma"},{"description":"Participants with Rhabdoid Tumor/ATRT.","id":"OG005","title":"Rhabdoid Tumor/ATRT"}],"paramType":"NUMBER","populationDescription":"The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of their tumor type. As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type.","reportingStatus":"POSTED","timeFrame":"Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)","title":"Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}